A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial.

Ziemssen T, Bajenaru OA, Carrá A, De Klippel N, de Sá JC, Edland A, Frederiksen JL, Heinzlef O, Karageorgiou KE, Lander Delgado RH, et al.

J Neurol. 2014 Aug 14. Epub 2014 Aug 14. PMID: 25119836. Abstract